UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery Sy
Alcon Research, LLC · Decision date Jan 8, 2026
What did the FDA decide?
FDA records P230012/S009 as a supplement to PMA P230012, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 8, 2026.
FDA approval order statement
Approval to implement the following manufacturing changes to UNIFEYE and UNIPEXY Gas Delivery Systems: 1) replacement of the existing welding system at Picocyl, the supplier responsible for producing the pico-cylinder component, and 2) design update to the fill head component of the ALL02 Gas Filling System.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Jan 8, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230012/S009
- Regulatory pathway
- PMA supplement
- Applicant
- Alcon Research, LLC
- Product code
- LPO
- Decision code
- OK30
- Decision date
- Jan 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Gases used within eye to place pressure on detached retina.
- Applicant
- Alcon Research, LLC
- Product code
- LPO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230012. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230012 · Original PMA
UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery Sy
P230012/S009 received
Application receipt date recorded by FDA.
P230012/S009 · FDA decision
30-Day Notice
P230012/S008 · Related supplement
UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System
P230012/S010 · Related supplement
UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery Sy
P230012/S011 · Related supplement
UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System
P230012/S012 · Related supplement
UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System
Timeline entries are records held by MedtechLedger for P230012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Research, LLC | PMA approval | Aug 26, 2024 | FDA | |
| Alcon Research, LLC | PMA supplement | Feb 10, 2026 | FDA | |
| Alcon Research, LLC | PMA supplement | Feb 17, 2026 | FDA | |
| Alcon Research, LLC | PMA supplement | May 28, 2026 | FDA | |
| Alcon Research, LLC | PMA supplement | Sep 30, 2026 | FDA |
Explore the linked device profile
Other records with product code LPO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Research, LLC | PMA supplement | Sep 30, 2026 | FDA | |
| Alcon Research, LLC | PMA supplement | May 28, 2026 | FDA | |
ISPAN Perfluoropropane C3F8 GasP900066/S017 | Airgas Therapeutics, LLC | PMA supplement | Apr 30, 2026 | FDA |
| Alcon Research, LLC | PMA supplement | Feb 17, 2026 | FDA | |
| Alcon Research, LLC | PMA supplement | Feb 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alcon Research, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 20511 Lake Forest Dr., Lake Forest, CA, 92630
Sources and methodology
- Original FDA record: P230012/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




